Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
Takeda's dengue vaccine prevents hospitalisations in TIDES trial
TAK-003 induces functional DENV cross-reactive cellular immmunity | Immunopaedia
Takeda's tetravalent dengue vaccine (TAK-003) receives first global approval for use in Indonesia without need for pre-vaccination testing | Asia Research News
Efficacy of the TAK-003 Vaccine for Protection Against Dengue Fever in Children, Adolescents - Infectious Disease Advisor
Efficacy of a Dengue Vaccine Candidate (TAK-003) in Healthy Children and Adolescents 2 Years after Vaccination. - Abstract - Europe PMC
Takeda's Biologics License Application (BLA) for Dengue Vaccine Candidate ( TAK-003) Granted Priority Review by U.S. Food and Drug Administration
TAK-003 vaccine: Trial shows Continued Protection against Dengue Fever - YouTube
Frontiers | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003
VisualAbstract: Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | 2 Minute Medicine
CONTRIBUTING TO THE FIGHT AGAINST DENGUE
Takeda: Dengue Vaccine Candidate Works Without Big Safety Risks
The Lancet on Twitter: "NEW—Tetravalent dengue vaccine (TAK-003) was well tolerated and efficacious against symptomatic #dengue in children aged 4-16 years regardless of serostatus before immunisation: a randomised, placebo-controlled, phase 3 trial
ABOUT DENGUE AND TAKEDA'S DENGUE VACCINE CANDIDATE (TAK-003)
Drug Overview: TAK-003 - Research and Markets
Takeda Dengue vaccine TAK-003 provides continued protection against dengue fever through 4.5 years in trial
Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents | NEJM
BioCentury - Nov. 23 Quick Takes: Priority review for Takeda's dengue vaccine
Takeda's dengue vaccine TAK-003 shows efficacy through 4.5 years in trial | Seeking Alpha
PharmaShots. - • The submission is based on a P-III TIDES trial assessing TAK-003 (0.5ml, SC) vs PBO in 20,000+ healthy children & adolescents aged 4-16yrs. to prevent dengue fever of any
Cross-reactivity of T cell responses following TAK-003... | Download Scientific Diagram
Structure of: (a) CYD -TDV (Dengvaxia); (b) TAK -003; (c) TV003 / TV005... | Download Scientific Diagram
